New advances in the treatment of atrial fibrillation: focus on stroke prevention

Abstract

Introduction: Atrial fibrillation (AF) is the most common arrhythmia and brings about significant mortality and morbidity as a result of heart failure and ischemic stroke. Besides vitamin K antagonists (VKA), several new pharmacological agents (nonvitamin K antagonist oral anticoagulants [NOACs]) and procedures have since been developed to improve stroke prevention efforts in AF.

Areas covered: This paper will discuss the antiplatelet agents, VKA and NOACs, and their efficacy and safety for stroke prevention in AF. Focus will be placed on the NOACs, their limitations and special considerations. A short assessment of other nonpharmacological antithrombotic procedures will also be made. An extensive PubMed search was used to identify suitable papers.

Expert opinion: Despite the advent of NOACs, the VKAs will remain as an important oral anticoagulant due to its versatility. However, convenience and limited food or drug interactions will make NOACs attractive options. The choice between various NOACs will depend on several important factors as illustrated below. Over time, the role for antiplatelet agents will gradually diminish. Left atrial appendage occlusion devices have shown promising results and may have the potential to change the way clinicians manage thromboembolism risks related to AF.

Keywords::

• antithrombotic treatment
• apixaban
• atrial fibrillation
• dabigatran
• edoxaban
• left atrial appendage closure device
• left atrial appendage occlusion device
• non-vitamin K antagonist oral anticoagulant
• rivaroxaban
• vitamin K antagonist
• warfarin

Notes

This box summarizes key points contained in the article.